Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic and localized scleroderma.

Lorinda Chung1, Jan Lin, Daniel E Furst

  • 1Department of Dermatology, Stanford University School of Medicine, CA 94305, USA.

Clinics in Dermatology
|September 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement.

Seminars in arthritis and rheumatism·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Integrated transcriptomic and epigenomic profiling reveals conserved molecular subtypes across systemic autoimmune diseases.

Annals of the rheumatic diseases·2026
Same author

Integrated single-cell transcriptomic analysis identifies <i>PF4</i> <sup><i>+</i></sup> <i>/PPBP</i> <sup><i>+</i></sup> megakaryocyte-like granulocytes associated with immune dysregulation in autoimmune diseases.

Biochemistry and biophysics reports·2026
Same author

Serum KL-6 and lung ultrasound B-lines: a combined non-invasive model for screening and predicting interstitial lung disease in idiopathic inflammatory myopathy.

RMD open·2026
Same author

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.

Seminars in arthritis and rheumatism·2026
Same journal

Letter to the editor in reply to "Ethics of Rising Trends in Dermatology Publications Using Large-Scale Databases".

Clinics in dermatology·2026
Same journal

Ethics of suggesting image-guided superficial radiation therapy on the pathology report.

Clinics in dermatology·2026
Same journal

Tanorexia: The Psychodermatology of Compulsive Tanning.

Clinics in dermatology·2026
Same journal

Ear manifestations of connective tissue diseases: A dermatologic, histopathologic, and clinicopathologic review.

Clinics in dermatology·2026
Same journal

Discovery of an intravenous drug injection site: A meticulous cutaneous examination provides the forensic dermatologic clue to a diagnosis of homicide.

Clinics in dermatology·2026
Same journal

Sherlock Holmes and the mystery of the deadly diet.

Clinics in dermatology·2026
See all related articles

Sclerosing skin conditions range from localized to fatal systemic forms. While some treatments target vascular and immune aspects of systemic sclerosis, effective therapies for the core fibrotic process remain elusive.

Area of Science:

  • Dermatology
  • Immunology
  • Pathology

Background:

  • Sclerosing skin conditions present a spectrum from localized skin issues to life-threatening systemic diseases.
  • Fibrotic processes are increasingly understood as complex disorders involving multiple molecular pathways, including vascular and immunological ones.

Purpose of the Study:

  • To review current understanding of sclerosing skin conditions and their underlying fibrotic mechanisms.
  • To evaluate existing therapeutic strategies for systemic sclerosis and identify gaps in treatment for the fibrotic process itself.

Main Methods:

  • Literature review of scleroderma and fibrosis research.
  • Analysis of current treatment modalities for systemic sclerosis.
  • Discussion of molecular pathways implicated in fibrosis.

Related Experiment Videos

Main Results:

  • Current therapies offer moderate success for vascular (e.g., pulmonary hypertension, Raynaud's, renal crisis) and immunological manifestations of systemic sclerosis.
  • Treatments like methotrexate and cyclophosphamide show efficacy for specific organ involvement (skin, lungs).

Conclusions:

  • Despite advances in managing vascular and immune aspects of systemic sclerosis, a definitive and effective therapy for the fundamental fibrotic process is still needed.
  • Further research into the heterogeneous mechanisms of fibrosis is crucial for developing targeted and curative treatments.